On June 20, 2023 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, reported that it will host an investor conference call and webcast to discuss lifileucel TIL therapy and the emerging melanoma treatment landscape on June 26, 2023, at 5:00 p.m. ET (Press release, Iovance Biotherapeutics, JUN 20, 2023, View Source [SID1234632795]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the one-hour event, the Iovance leadership team will provide a brief recap of the C-144-01 trial and clinical data, defined regulatory pathway, and pre-commercial activities for lifileucel in advanced post-anti-PD-1 melanoma. A multidisciplinary panel of key opinion leaders (KOLs) will discuss the disease burden and unmet needs for advanced melanoma patients within current treatment practices, perspectives on TIL therapy and the emerging landscape, and preparations for broad adoption of lifileucel and cell therapies within their treatment centers.
The KOL roundtable will be moderated by Dr. Brian Gastman, Executive Vice President, Medical Affairs at Iovance and a practicing surgeon who consults and operates on cancer patients at the Cleveland Clinic. Prior to his recent arrival at Iovance, Dr. Gastman led the melanoma clinical trials team, including as lead investigator on numerous trials of TIL and other cell therapies, as Co-Medical and Surgical Director of Cleveland Clinic and Taussig Cancer Center’s melanoma and high-risk skin cancer program.
To participate in the webcast Q&A, please register at https://register.vevent.com/register/BI5f5b5df5576e42d2bf3535abcc93c3df, or to view only register at View Source The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will also be available for one year.
Virtual KOL Event Agenda
Introduction: Recap of Lifileucel TIL Therapy Development & Regulatory Pathway
Multidisciplinary KOL Roundtable:
Perspectives on Lifileucel and Advanced Melanoma Treatment Landscape
Participant Title TIL Experience
Brian Gastman, M.D. (moderator) EVP, Medical Affairs at Iovance Biotherapeutics and practicing surgeon at the Cleveland Clinic Lead investigator of TIL trials at Cleveland Clinic
Krishna Komanduri, M.D. Professor and Chief, Division of Hematology and Oncology, Dept. of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, University of California San Francisco (UCSF) Chair of TIL Working Group (TIL-WG), dedicated to educating healthcare practitioners about TIL therapy
Past President, American Society for Transplantation and Cellular Therapy (ASTCT)
Mario Sznol, M.D. Medical oncologist at Yale Medicine; co-director of the Cancer Immunology Program at Yale Cancer Center Iovance Scientific Advisory Board member
Live Audience Q&A Session